Clinical Trial Update: VITAL - Individualising Therapy for Neovascular AMD With Aflibercept [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating how aflibercept can be individualized to treat neovascular age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Eylea) (aflibercept)

Snippet

Sponsor: Moorfields Eye Hospital NHS Foundation Trust | Conditions: Age Related Macular Degeneration | Phase 4 | Status: COMPLETED